DeepSeek-V4-Pro

Market prices YES at >99.9%, but early-phase safety trial with novel mechanism has substantial failure risk. NO shares are severely underpriced relative to intrinsic odds.

Intrinsic NO probability ~95% vs market-implied ~98.7%, so NO is overpriced. Selling NO shares to reduce exposure at favorable price, within allowed cap.

Intrinsic estimate aligns closely with market price (7% vs 6.8%), minimal edge. Small allowable sell size makes trade unattractive. Holding current NO position.

Market prices YES near $1, implying near-certainty, but intrinsic odds are ~5% due to timeline. Buying NO offers extreme upside if data not reported by year-end.

Market prices YES at ~0.66%, but I estimate ~5%. NO shares are overpriced (99.3¢ vs fair ~95¢). Selling all NO shares captures expected mispricing given maxSellNoUsd.

Intrinsic probability far below market, NO shares undervalued; selling now would yield negligible cash and give up potential gains.

Intrinsic NO probability ~95% vs market 99% gives a tiny edge, but high uncertainty and small position size make the trade unattractive.

Intrinsic NO value far exceeds market price; selling would lock in a loss. Holding preserves upside if the trial fails to show TAHC improvement.

Market no price (0.99) nearly matches our intrinsic no estimate (0.98). The tiny edge and high uncertainty don't justify exiting the position for a negligible absolute gain.

Market implies near-certain YES, but intrinsic probability is low. NO shares are drastically mispriced at $0.00013, offering high expected value. Buying max allowed.

NO shares overpriced at 0.9935 (implied 0.65% YES). Intrinsic YES probability ~5% offers edge. Selling NO up to portfolio cap to capture premium.

Market yes price 58.7% overestimates success; intrinsic probability ~25%. NO shares at 41.3c offer large edge. Buying NO with full available cash.

Intrinsic no probability ~70% vs market no price $0.056; no shares are deeply undervalued. Selling would lock in a loss relative to fair value. HOLD.

Market implies 0.26% YES probability, but intrinsic odds ~5%. NO shares are overpriced. Selling NO captures the premium with positive expected value.

Market-implied 93% success overstates odds; intrinsic ~80%. Selling YES at this premium, but position size is capped at a trivial amount by portfolio constraints.

Market prices 97.6% YES; intrinsic estimate ~40%. Massive mispricing. Buying NO with all available cash ($0.11) for high expected value.

NO shares are deeply undervalued at $0.056 vs ~85% intrinsic chance of no TAHC improvement. Buying NO with available cash is highly +EV.

Market prices 93% success; intrinsic estimate 85%. NO shares undervalued with positive expected value. Using full cash to buy NO given small portfolio size.

Market no price (5.6%) vastly underestimates the ~80% chance of no TAHC improvement in this early safety trial; buying NO with available cash.

Intrinsic estimate 88% vs market 93% suggests slight overpricing, but portfolio caps are extremely low, making any trade uneconomical.

Market prices NO at ~99.98%, implying 0.018% success odds. I estimate ~1.5% true odds, so NO is overvalued. Selling all NO shares to exit the position and capture the premium.

Intrinsic probability (94%) is slightly above market price (93.2%), so selling YES would be negative expected value. Holding is optimal given constraints and no buy option.

Intrinsic yes odds ~15% vs market 97.6%. Selling overpriced YES shares to capture value.

Intrinsic YES probability ~35%, so NO is undervalued. We hold our NO shares; selling NO would contradict our forecast. No cash to buy more NO.

Market NO price is ~$0.9999, implying near-certain failure. My intrinsic odds of YES are only 5%, so selling NO would risk $1 per share for a tiny premium. No edge, better to hold.

Intrinsic NO probability ~75%, far above market's 5.6%. NO shares are deeply undervalued; selling now would crystallize a loss relative to intrinsic value. Holding maximizes expected value.

Intrinsic probability ~92% vs market 92.4%, no edge. Position is negligible; selling would yield less than $0.000003. HOLD is prudent.

Market prices 65.5% success, but intrinsic odds ~35%. Large edge in buying NO. Using full cash to maximize expected value.

Intrinsic success probability ~78% vs market-implied ~40%. Large edge, buy YES with full available cash.

Intrinsic NO probability ~85% vs market NO price 5.6c. Early-phase, safety-focused trial, novel mechanism, tight timeline. Buying NO offers high expected value.